Assessment of neoadjuvant chemotherapy in breast cancer patients / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 867-870, 2006.
Artículo
en Chino
| WPRIM
| ID: wpr-316279
ABSTRACT
<p><b>OBJECTIVE</b>To assess the response of neoadjuvant chemotherapy and its influencing factors in the breast cancer patients.</p><p><b>METHODS</b>171 patients with stage II or operable stage III breast cancers were treated with neoadjuvant chemotherapy before surgery between January 2004 and May 2005. Of these, 160 received and completed > or =3 cycles of neoadjuvant chemotherapy, 11 received only 2 cycles. The regimens of neoadjuvant chemotherapy were CEF (CTX, Epirubicin, 5-Fu); NE (Navelbine, Epirubicin); TEC (Taxotere, Epirubicin, CTX). Response of neoadjuvant chemotherapy was evaluated in all patients by palpation, ultrasonography and pathological methods.</p><p><b>RESULTS</b>Complete response rate and clinical objective response rate determined by clinical palpation (cCR, cOR), ultrasonography (sCR, sOR) and pathology (pCR) was 18.7% and 88.3%; 4.1% and 74.9%; 15.2%, respectively. The correspondence rate of the pCR with cCR and sCR was 43.8% and 42.9%, respectively. It was showed by univariate analysis that patient whose tumor was < or =3 cm in diameter, or ER negative or grade 3 were more likely to achieve a pCR than those whose tumor was >3 cm, or ER positive or grade 1. Logistic regression analysis showed that only tumor size was the significant predictive factor for response to neoadjuvant chemotherapy in patients with primary breast cancer.</p><p><b>CONCLUSION</b>Patient with small, or ER negative or grade 3 tumor may have better pathological response to neoadjuvant chemotherapy, particularly, the tumor size is more predictive of pCR. Palpation or ultrasonography may have a tendency either to under- or to overestimate pCR. Breast neoplasms/drug therapy;</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Cirugía General
/
Vinblastina
/
Inducción de Remisión
/
Neoplasias de la Mama
/
Epirrubicina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptores de Progesterona
/
Receptores de Estrógenos
/
Modelos Logísticos
Tipo de estudio:
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS